The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $12.88

Today's change0.00 0.00%
Updated July 28 4:00 PM EDT. Delayed by at least 15 minutes.
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $12.88

Today's change0.00 0.00%
Updated July 28 4:00 PM EDT. Delayed by at least 15 minutes.

Nektar Therapeutics closed at (U.S.)$12.88.

Over the last five days, shares have gained 2.22%, but are down 16.90% for the last year to date. Shares have outperformed the S&P 500 by 12.28% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $12.88
  • High--
  • Low--
  • Bid / Ask(U.S.) $12.50 / (U.S.) $14.80
  • YTD % change-16.90%
  • Volume0
  • Average volume (10-day)1,341,895
  • Average volume (1-month)1,344,086
  • Average volume (3-month)1,836,592
  • 52-week range(U.S.) $9.51 to (U.S.) $17.53
  • Beta1.54
  • Trailing P/E74.27×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.17
Updated July 28 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue1092013329
Total other revenue--------
Total revenue1092013329
Gross profit1001312423
Total cost of revenue8695
Total operating expense66575351
Selling / general / administrative1012910
Research & development47383437
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--0----
Other operating expenses, total--------
Operating income43-3780-23
Interest income (expense), net non-operating-9-10-10-10
Gain (loss) on sale of assets--------
Other--------
Income before tax34-4771-32
Income after tax34-4671-33
Income tax, total0-100
Net income34-4671-33
Total adjustments to net income--------
Net income before extra. items34-4671-33
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items34-4671-33
Inc. avail. to common incl. extra. items34-4671-33
Diluted net income34-4671-33
Dilution adjustment--------
Diluted weighted average shares136129132127
Diluted EPS excluding extraordinary itemsvalue per share0.25-0.350.53-0.26
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share0.25-0.350.53-0.26